There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report) with bullish sentiments.
Merck & Company (MRK)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $100.00. The company’s shares closed last Wednesday at $76.05.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $90.31, which is a 19.7% upside from current levels. In a report issued on December 8, Wells Fargo also initiated coverage with a Buy rating on the stock with a $90.00 price target.
See today’s best-performing stocks on TipRanks >>
Mereo Biopharma Group Plc (MREO)
Needham analyst Gil Blum maintained a Buy rating on Mereo Biopharma Group Plc today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.64, close to its 52-week low of $1.51.
According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Mereo Biopharma Group Plc is a Strong Buy with an average price target of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRK:
